Detalhe da pesquisa
1.
Radiotheranostics in oncology: Making precision medicine possible.
CA Cancer J Clin;
73(3): 255-274, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36622841
2.
Improved pharmacokinetics and enhanced efficacy of the vancomycin derivative FU002 using a liposomal nanocarrier.
Nanomedicine;
56: 102731, 2024 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38158147
3.
FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease.
Radiology;
306(2): e220749, 2023 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36594838
4.
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.
Eur J Nucl Med Mol Imaging;
50(5): 1466-1486, 2023 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36604326
5.
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).
Eur J Nucl Med Mol Imaging;
50(9): 2830-2845, 2023 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37246997
6.
[68 Ga]Ga-FAPI uptake correlates with the state of chronic kidney disease.
Eur J Nucl Med Mol Imaging;
49(10): 3365-3372, 2022 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34988624
7.
Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model.
Eur J Nucl Med Mol Imaging;
49(3): 871-880, 2022 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34537893
8.
Effects of Different Basal Cell Culture Media upon the Osteogenic Response of hMSCs Evaluated by 99mTc-HDP Labeling.
Int J Mol Sci;
23(11)2022 Jun 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35682966
9.
99mTc-HDP Labeling-A Non-Destructive Method for Real-Time Surveillance of the Osteogenic Differentiation Potential of hMSC during Ongoing Cell Cultures.
Int J Mol Sci;
23(24)2022 Dec 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36555513
10.
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.
Lancet Oncol;
22(8): 1115-1125, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34246328
11.
Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma.
Eur J Nucl Med Mol Imaging;
48(6): 1932-1943, 2021 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33336264
12.
Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients.
Eur J Nucl Med Mol Imaging;
48(9): 2925-2934, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33543325
13.
Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity.
Eur J Nucl Med Mol Imaging;
49(1): 54-63, 2021 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34448031
14.
68Ga-FAPI-PET/CT in patients with various gynecological malignancies.
Eur J Nucl Med Mol Imaging;
48(12): 4089-4100, 2021 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34050777
15.
High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics.
Eur J Nucl Med Mol Imaging;
49(1): 385-389, 2021 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34226953
16.
Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients.
Eur J Nucl Med Mol Imaging;
48(13): 4377-4385, 2021 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34137945
17.
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.
Eur J Nucl Med Mol Imaging;
48(5): 1626-1638, 2021 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33604691
18.
Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging.
Ann Rheum Dis;
79(11): 1485-1491, 2020 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32719042
19.
68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer-a modified protocol compared with the common protocol.
Eur J Nucl Med Mol Imaging;
47(3): 624-631, 2020 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31673789
20.
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.
Hematol Oncol;
38(3): 244-256, 2020 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32067259